WHAT'S NEW IN PCR VERSION 16.1.9

Smoking Cessation Improvements

Background

The smoking cessation support tool assessment was introduced in PCR version 9 in 2014. Active use of the assessment had afforded the opportunity to assess areas for improvement. A series of improvements were identified by various stakeholders who represent the PCR users.

Changes

Following changes have been made in the Smoking Cessation support tool assessment in PCR.

- PCR will now support creation of new smoking cessation quit attempts for a patient while previous quit attempts for the patient are still open in the system.
- PCR will auto-close smoking cessation assessments which are still open after 20 weeks from the quit attempt date set in assessment. Where quit attempt date is not available, 20 weeks will be calculated from the date the assessment was last modified in the system.

| Γ | Close quit attempt | | Τ |
|---|--|---------------------------------|-------|
| | Close quit attempt complete Close quit attempt completed by | Yes : Auto-close | |
| | Close quit attempt completed on | 20-Mar-2024 | |
| | Unique reference PCR-980 C0DE4C | B2679-301A-4E7E-B17B- IECDD1 | |

Figure 1: Attempt auto-closed by system

- New care issues linked to Smoking cessation quit attempts can no longer be created in the system.
- Minimum Data Set (MDS) is now referred to as Mandatory progress report in PCR
- 'Contact' or 'Record Contact' is now referred to as 'Patient's Progress' in PCR
- 'Initial Data Capture' is now referred to as 'Pre-Quit Registration' in PCR
- Within 'Pre-Quit Registration' page, Varenicline related additional questions are now with new text.

| Pharmaceutical usage | | |
|---|--------------------------------|-------------|
| Pharmaceutical usage | Varenicline only | |
| Total number of weeks of known product use | 0 🗸 | |
| A Varenicline risk assessment must be comp | pleted prior to supply | |
| Does the client wish to use Varenicline? | ⊖Yes ⊖No | |
| Varenicline risk assessment must be completed before supply is made, contacting GP if there is any question over suitability. If supply is made, client's GP must be informed. | | |
| Notes | | |
| | ^ | |
| | ~ | |
| | | Save Cancel |
| Figure | e 2: new Varenicline questions | |

• Within 'Pre-Quit Registration' page, a new free text area is introduced to add any notes/comments about the quit attempt.

| Pharmaceutical usage | | |
|---|------------------------|-------------|
| Pharmaceutical usage | Varenicline only | |
| Total number of weeks of known product use | 0 🗸 | |
| A Varenicline risk assessment must be comp | pleted prior to supply | |
| Does the client wish to use Varenicline? | ⊖Yes ⊖No | |
| Varenicline risk assessment must be completed before supply is made, contacting GP if there is any question over suitability. If supply is made, client's GP must be informed. | | |
| Notes | | ור |
| | \sim | |
| | | Save Cancel |

Figure 3: Notes about attempt

• Within 'Pre-Quit Registration' page, guidance is provided to check for any interactions that the patient's existing medication might have with use of tobacco. Any observations can now be noted in a dedicated text area for the same.

| Check whether client takes any medication that interacts with smoking tobacco - <u>SPS smoking interactions</u> Note any identified issue and actions taken in the below box. | |
|--|---|
| Notes on medicine interaction | _ |

Figure 4: Guidance and notes about medicine interactions

• If there are patients, linked to the pharmacy, who have a smoking cessation quit attempt mandatory progress report due in next 7 days, a warning text will now be visible on patient search page in PCR.

What's new in PCR 16.1.9

| Search crite | | | | a manage press | e Yellow card He | | |
|---------------|------|-------------|---------------------------|----------------|------------------|------|--|
| Family name | | | | 7 | | | |
| Given name | | | | Ξ. | | | |
| Date of birth | | | | | | | |
| | | e.g: 31-07- | 2015 for the 31st of July | 2015 | | | |
| Postcode | | | | | | | |
| CHI | | | | | | | |
| | | | Search | | | | |
| Search resi | ilte | | | | | | |

Figure 5: Warning about expiring mandatory progress reports